Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Tazobactam is a beta-lactamase inhibitor used in combination with certain beta-lactam antibiotics, such as piperacillin or ceftolozane, to treat bacterial infections. It works by irreversibly inhibiting bacterial beta-lactamase enzymes, which are responsible for breaking down and inactivating many penicillin and cephalosporin antibiotics. By blocking these enzymes, tazobactam protects the partner antibiotic from degradation and extends its spectrum of activity against organisms that produce beta-lactamases. Tazobactam itself has minimal antibacterial activity when used alone and is not administered as a monotherapy[2].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on tazobactam.